Glaxo Sues Dr. Reddy's Over Generic Imitrex

Law360, New York (December 30, 2003, 12:00 AM EST) -- GlaxoSmithKline PLC sued Dr. Reddy’s Laboratories in the U.S. District Court for the Southern District in New York to stop the Indian generics maker from marketing copies of migraine medicine Imitrex before the expiration of Glaxo's patent.

The suit claims Hyderabad-based Dr. Reddy’s has submitted an abbreviated new-drug application (ANDA) to the Food and Drug Administration (FDA) for approval to market generic copies of migraine medicine Imitrex before the expiration of Glaxo's patent.

Glaxo's patent on the active ingredient in Imitrex, sumatriptan succinate, expires on Aug....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.